98% up by HPLC Saxagliptin 361442-04-8

Saxagliptin is a highly potent dipeptidyl peptidase-4 (Dipeptidyl Peptidase 4, DPP-4) inhibitor. By selectively inhibiting DPP-4, it can increase endogenous glucagon-like peptide-1 ( Glucagon-like Peptide-1, GLP-1) and glucose-dependent insulinotropic peptide (Glucose-dependent Insulinotropic Peptide, GIP) levels, thereby regulating blood sugar.

Saxagliptin alone can effectively control blood sugar. Combination therapy with metformin or sulfonylurea can control blood sugar earlier and more effectively, improve the rate of patients' blood sugar compliance, and is safe and well tolerated. The HbA1c-lowering effect of saxagliptin was consistent across age, sex, ethnicity, body mass index (BMI), geographic distribution, and duration of diabetes, and was applicable to most patients with type II diabetes.